Stuart Lutzker is listed as a director on 2 SEC Form D filings by 1 issuer between Feb 2022 and Dec 2022: ArriVent Biopharma, Inc. (Newtown Square, PA — biotechnology — 2022; $150M reported sold to 17 investors).
What this means One deal on file with the SEC, filed Dec 2022. A Form D is the notice a company files after it starts selling a private investment — it is a notice, not an approval.
Listed alongside Cong Xu (2 shared filings), Jason Zhang (2 shared filings), Zhengbin (Bing) Yao (2 shared filings), Bahija Jallal (1 shared filing), Carl L. Gordon (1 shared filing) and 1 others.
What this means These are the other officers, directors or promoters the companies named on the same forms — the team around Stuart. Each name links to their own page.
Public records searched: federal courts (CourtListener / RECAP), SEC enforcement releases, state securities regulators (AZ, CA, DE, TX, WA) — 4 court cases matching the name, 2 bankruptcy cases matching the name listed in Key records below.
What this means 6 records came back, including 1 court case still open — open cases can take years and cost money. Each one is listed below with a link to the original document and a line saying why it matched. A name match is not proof it is the same person or company — read the why line and the document. Being sued or named in a release is an accusation, not a finding.
We compared 2 public filings for Stuart Lutzker and found 2 differences: Offering amount changed between filings; No amendment in the last 12 months on an offering that may still be open.
What this means These are differences between the sponsor's own SEC filings — both values, dates and sources are listed in Key records, section 4. Most have ordinary explanations; ask the sponsor.